SMTL ID : 7n5y.1

Fragment-Based Drug Design of a Novel, Covalent Bruton's Tyrosine Kinase Inhibitor

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 1.85 Å

Oligo State

monomer

Ligands

1 x IMD: IMIDAZOLE(Non-covalent)

IMD.1: 4 residues within 4Å: Chain A: R.186, M.220, E.223, F.225 1 PLIP interactions: 1 interactions with chain A Hydrogen bonds: A:E.223

1 x 0CI: 5-(1-{[(3S)-1-propanoylpyrrolidin-3-yl]oxy}isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one(Covalent)

0CI.2: 15 residues within 4Å: Chain A: L.32, G.33, T.34, V.40, A.52, K.54, T.98, E.99, Y.100, M.101, A.102, G.104, C.105, R.149, L.152 10 PLIP interactions: 10 interactions with chain A Hydrophobic interactions: A:L.32, A:L.32, A:L.32, A:V.40 Hydrogen bonds: A:K.54, A:T.98, A:E.99, A:M.101 Water bridges: A:K.54, A:N.108

1 x DMS: DIMETHYL SULFOXIDE(Non-functional Binders)

DMS.3: 2 residues within 4Å: Chain A: T.27, F.28 1 PLIP interactions: 1 interactions with chain A Hydrogen bonds: A:F.28

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Sabat, M. et al., Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 ( S )-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3 H -1,2,4-triazol-3-one, by Fragment-Based Drug Design. J.Med.Chem. (2021)

Release Date

2021-09-08

Peptides

Tyrosine-protein kinase BTK: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Tyrosine-protein kinase BTK

Related Entries With Identical Sequence